Tagged with Investment,

clinical trials The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303 in 2012, with 367 clinical trials performed by local companies. In the same year, Seoul was ranked the number one…

biotech Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their second generation botulinum toxin product that will be commercialized globally (outside of Japan and Korea) by Botox manufacturer Allergan. What…

World Medicine The founder and chairman of the rapidly expanding World Medicine group of companies discusses his firm’s international expansion strategy, how he came to the decision to invest in production and R&D facilities in Turkey, and the strong support World Medicine has from the Turkish government. How did you originally come…

Menarini Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by their current capacity which has minimal excess in some specific lines of production. Uğur Bingöl, the new managing director discusses…

R&D Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses this facility’s role as a role model in the industry, and how the country can improve investment incentives to better…

R&D “When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he gazes down at the busy, sundrenched streets of Seoul below. “I thought that the global business of Korean pharmaceutical companies…

Exports The director general of Afric-Phar explains why it is difficult for the local players to compete with multinationals, how the Moroccan market is being reformed for the better and why companies should be looking to Africa to boost their growth prospects.   What are Afric-Phar’s strengths that make it an…

Sanofi The president and director general of Sanofi Morocco talks about the impact of public/private partnerships for the development of the Moroccan health sector, explains why 2013 was the African year for Sanofi and stresses the importance of visibility if Sanofi is to continue investing in large regional projects in the…

GSK Morocco has become GSK’s regional hub thanks to the quality of human capital in the country, explains the company’s area director, president and general manager for North Africa, who also comments on the reason why she remains optimistic for the future of Moroccan pharmaceutical industry.   We have heard from the industry…

Novartis The country president and general director of Novartis Morocco discusses the impact of the price cuts on the pharma market, the need to change the health culture in the country and the importance of Morocco as a hub.   As well as being the country president of Novartis Morocco, you…

Alexion Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put in place, and how Alexion is communicating with patients’ associations and medical community to raise awareness about ultra-rare diseases.  …

FDA Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s pharmaceutical sector.   What are the primary goals of the ministry today? Since the Ministry of Food and Drug Safety…